Ambrx Competitors and Similar CompaniesClear all
Ambrx's competitors and similar companies include Pharming Group, ProQR Therapeutics, Redpin Therapeutics and Precigen.
 Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. |  Pharming Group Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. |  ProQR Therapeutics ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases. |  Redpin Therapeutics Redpin Therapeutics is a gene therapy company providing cell therapies that address diseases of the nervous system. |  Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. | |
Founding Date | Founding Date 2003 | Founding Date 1988 | Founding Date 2012 | Founding Date 2017 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations Leiden, NL HQ Leiden, NL | Locations Leiden, NL HQ Cambridge, US | Locations New York, US HQ New York, US | Locations Germantown, US HQ Gent, BE Sioux Center, US |
Employees | Employees 70 | Employees 404 | Employees 166 | Employees 2 | Employees 601 |
Valuation ($) | Valuation ($) 1.8 b | Valuation ($) 590.3 m | Valuation ($) 281.8 m | Valuation ($) N/A | Valuation ($) 246.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) $376.1m (FY, 2025) | Revenue (est.) €15.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $9.7m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $41.6m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $341m (FY, 2025) | Gross profit €16.3m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($78m) (FY, 2022) | Net income $2.5m (FY, 2025) | Net income (€42.2m) (FY, 2025) | Net income N/A | Net income ($250.6m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 347.9m | Total funding raised N/A | Total funding raised $ 57.8m | Total funding raised $ 17m | Total funding raised $ 379m |
For sources of this data, please see the company profile
View Company Profiles
Pharming Group
HQ
Leiden, NL
Employees
404
Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.
View companyProQR Therapeutics
HQ
Leiden, NL
Employees
166
ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases.
View companyRedpin Therapeutics
HQ
New York, US
Employees
2
Redpin Therapeutics is a gene therapy company providing cell therapies that address diseases of the nervous system.
View companyPrecigen
HQ
Germantown, US
Employees
601
Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View company